Riluzole blocks human muscle acetylcholine receptors

Journal of Physiology

Volumn 590, Issue 10, 2012, Pages 2519-2528

  Deflorio, Cristina ^a   Palma, Eleonora ^a,b   Conti, Luca ^a   Roseti, Cristina ^b   Manteca, Alessia ^a   Giacomelli, Elena ^c   Catalano, Myriam ^a,d   Limatola, Cristina ^a,d   Inghilleri, Maurizio ^c   Grassi, Francesca ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; RECOMBINANT RECEPTOR; RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; INTRACELLULAR SIGNALING; MALE; MUSCLE ACTION POTENTIAL; MUSCLE DENERVATION; NERVE STIMULATION; NEUROMUSCULAR DISEASE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SYNAPTIC TRANSMISSION;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CHOLINERGIC ANTAGONISTS; FEMALE; HEK293 CELLS; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NEUROPROTECTIVE AGENTS; OOCYTES; RECEPTORS, CHOLINERGIC; RILUZOLE; SATELLITE CELLS, SKELETAL MUSCLE; XENOPUS LAEVIS;

EID: 84861012507     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2012.230201     Document Type: Article

References (36)

1. 2+ spikes in mouse myotubes during myogenesis. J Physiol 568, 171-180.
2. Bellingham MC (2011). A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther 17, 4-31.
3. Bouzat C & Barrantes FJ (1996). Modulation of muscle nicotinic acetylcholine receptors by the glucocorticoid hydrocortisone. Possible allosteric mechanism of channel blockade. J Biol Chem 271, 25835-25841.
4. Chandu BR, Nama S, Kanala K, Challa BR, Shaik RP & Khagga M (2010). Quantitative estimation of riluzole in human plasma by LC-ESI-MS/MS and its application to a bioequivalence study. Anal Bioanal Chem 398, 1367-1374.
5. Connold AL & Vrbova G (1991). Temporary loss of activity prevents the increase of motor unit size in partially denervated rat soleus muscles. J Physiol 434, 107-119.
6. Colquhoun D (1998). Binding, gating, affinity and efficacy: The interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125, 924-947.
7. Dadon-Nachum M, Melamed E & Offen D (2011). The 'dying-back' phenomenon of motor neurons in ALS. J Mol Neurosci 43, 470-477.
8. Di Angelantonio S, Piccioni A, Moriconi C, Trettel F, Cristalli G, Grassi F & Limatola C (2011). Adenosine A2A receptor induces protein kinase A-dependent functional modulation of human α3β4 nicotinic receptor. J Physiol 589, 2755-2766.
9. 2+ permeability of the human endplate ACh receptor. J Physiol 579, 671-677.
10. Eisen A & Swash M (2001). Clinical neurophysiology of ALS. Clin Neurophysiol 112 2190-2201.
11. Forman SA (1999). A hydrophobic photolabel inhibits nicotinic acetylcholine receptors via open-channel block following a slow step. Biochemistry 38, 14559-14564.
12. 2+ overloading. J Physiol 573, 35-43.
13. García-Colunga J, Awad JN & Miledi R (1997). Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc Natl Acad Sci U S A 94, 2041-2044.
14. Grassi F (1999). 5-Hydroxytryptamine blocks the fetal more potently than the adult mouse muscle acetylcholine receptor. Pflugers Arch 437, 903-909.
15. Harper CM, Fukodome T & Engel AG (2003). Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 60, 1710-1713.
16. Katz B & Miledi R (1964). Further observations on the distribution of actylcholine-reactive sites in skeletal muscle. J Physiol 170, 379-388.
17. Krause RM, Hamann M, Bader CR, Liu JH, Baroffio A & Bernheim L (1995). Activation of nicotinic acetylcholine receptors increases the rate of fusion of cultured human myoblasts. J Physiol 489, 779-790.
18. Krnjevic K & Straughan DW (1964). The release of acetylcholine from the denervated rat diaphragm. J Physiol 170, 371-378.
19. Le Liboux A, Cachia JP, Kirkesseli S, Gautier JY, Guimart C, Montay G, Peeters PA, Groen E, Jonkman JH & Wemer J (1999). A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers. J Clin Pharmacol 39, 480-486.
20. Liu Y, Padgett D, Takahashi M, Li H, Sayeed A, Teichert RW, Olivera BM, McArdle JJ, Green WN & Lin W (2008). Essential roles of the acetylcholine receptor γ-subunit in neuromuscular synaptic patterning. Development 135, 1957-1967.
21. Miledi R, Palma E & Eusebi F (2006). Microtransplantation of neurotransmitter receptors from cells to Xenopus oocyte membranes: new procedure for ion channel studies. Methods Mol Biol 322, 347-355.
22. Mohammadi B, Lang N, Dengler R & Bufler J (2002). Interaction of high concentrations of riluzole with recombinant skeletal muscle sodium channels and adult-type nicotinic receptor channels. Muscle Nerve 26, 539-545.
23. Moriconi C, Di Castro MA, Fucile S, Eusebi F & Grassi F (2010). Mechanism of verapamil action on wild-type and slow-channel mutant human muscle acetylcholine receptor. J Neurochem 114, 1231-1240.
24. Musarò A (2010). State of the art and the dark side of amyotrophic lateral sclerosis. World J Biol Chem 1, 62-68.
25. Neher E & Steinbach JH (1978). Local anaesthetics transiently block currents through single acetylcholine-receptor channels. J Physiol 277, 153-176.
26. Noh KM, Hwang JY, Shin HC & Koh JY (2000). A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C. Neurobiol Dis 7, 375-383.
27. Oppenheim RW, Prevette D, D'Costa A, Wang S, Houenou LJ & McIntosh JM (2000). Reduction of neuromuscular activity is required for the rescue of motoneurons from naturally occurring cell death by nicotinic-blocking agents. J Neurosci 20, 6117-6124.
28. Palma E, Esposito V, Mileo AM, Di Gennaro G, Quarato P, Giangaspero F, Scoppetta C, Onorati P, Trettel F, Miledi R & Eusebi F (2002). Expression of human epileptic temporal lobe neurotransmitter receptors in Xenopus oocytes: An innovative approach to study epilepsy. Proc Natl Acad Sci U S A 99, 15078-15083.
29. Palma E, Inghilleri M, Conti L, Deflorio A, Frasca V, Manteca A, Pichiorri F, Roseti C, Torchia G, Limatola C, Grassi F & Miledi R (2011). Physiological characterization of human muscle acetylcholine receptors from ALS patients. Proc Natl Acad Sci U S A 108, 20184-20188.
30. Pestronk A & Drachman DB (1985). Motor nerve terminal outgrowth and acetylcholine receptors: inhibition of terminal outgrowth by α-bungarotoxin and anti-acetylcholine receptor antibody. J Neurosci 5, 751-758.
31. Spitzmaul G, Gumilar F, Dilger JP & Bouzat C (2009). The local anaesthetics proadifen and adiphenine inhibit nicotinic receptors by different molecular mechanisms. Br J Pharmacol 157, 804-817.
32. Steinbach JH & Chen Q (1995). Antagonist and partial agonist actions of d-tubocurarine at mammalian muscle acetylcholine receptors. J Neurosci 15, 230-240.
33. Terrado J, Burgess RW, DeChiara T, Yancopoulos G, Sanes JR & Kato AC (2001). Motoneuron survival is enhanced in the absence of neuromuscular junction formation in embryos. J Neurosci 21, 3144-3150.
34. Witzemann V, Brenner HR & Sakmann B (1991). Neural factors regulate AChR subunit mRNAs at rat neuromuscular synapses. J Cell Biol 114, 125-141.
35. Yampolsky P, Gensler S, McArdle J & Witzemann V (2008). AChR channel conversion and AChR-adjusted neuronal survival during embryonic development. Mol Cell Neurosci 37, 634-645.
36. Yampolsky P, Pacifici PG & Witzemann V (2010). Differential muscle-driven synaptic remodeling in the neuromuscular junction after denervation. Eur J Neurosci 31, 646-658.